Antibody responses to hepatitis A virus vaccination in Thai HIV-infected children with immune recovery after antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 30, Issue 3, 2011, Pages 256-259

  Sudjaritruk, Tavitiya ^a   Sirisanthana, Thira ^b   Sirisanthana, Virat ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

antibody response; hepatitis A vaccination; HIV infected children

Indexed keywords

AGE; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONVALESCENCE; GENDER; HEPATITIS A VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PREVALENCE; PRIORITY JOURNAL; VACCINATION; VIROTHERAPY;

EID: 79951679948     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f812f8     Document Type: Article

References (19)

1. Laurence J. Viral cofactors in the immune pathogenesis and clinical manifestations of HIV infection. In: Wormser GP, ed. AIDS and Other Manifestations of HIV Infection. 4th ed. New York: Elsevier; 2004:117-127.
2. Scherpbier HJ, Hilhorst MI, Kuijpers TW. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis. 2003;37:828-830. (Pubitemid 37153664)
3. Brück S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res. 2008;13:343-348.
4. ACIP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep Recomm Rep. 2006;55:1-23.
5. Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet. 2004;363:1860-1867. (Pubitemid 38748641)
6. Tasker SA, Wallace MR, Rubins JB, et al. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis. 2002;34:813-821. (Pubitemid 34194853)
7. Kemper CA, Haubrich R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis. 2003;187:1327-1331. (Pubitemid 36438975)
8. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis. 2004;39:1207-1213. (Pubitemid 40169321)
9. World Health Organization. Case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Recommendation for a public health approach. Geneva: World Health Organization; 2006.
10. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis. 2006;193:302-311. (Pubitemid 43113494)
11. Pancharoen C, Mekmullica J, Kasempimolporn S, et al. Seroprevalence of hepatitis A virus antibody among children and young adults in Bangkok. J Med Assoc Thai. 2001;84:1477-1480.
12. Castillo de Febres O, Chacon de Petrola M, Casanova de Escalona L, et al. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine. 1999;18:656-664.
13. Gouvea AF, De Moraes-Pinto MI, Ono E, et al. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis. 2005;41:544-548. (Pubitemid 41099652)
14. Siberry GK, Coller RJ, Henkle E, et al. Antibody response to hepatitis A immunization among human immunodeficiency virus-infected children and adolescents. Pediatr Infect Dis J. 2008;27:465-468.
15. Rigaud M, Borkowsky W, Muresan P, et al. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis. 2008;198:1123-1130.
16. Abarca K, Ibánez I, Perret C, et al. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis. 2008;12:270-277. (Pubitemid 351539101)
17. López EL, Del Carmen Xifró M, Torrado LE, et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J. 2001;20:48-52. (Pubitemid 32066176)
18. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994;44:446-451.
19. Weinberg A, Huang S, Fenton T, et al. Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. J Acquir Immune Defic Syndr. 2009;52:17-24.